YM 38336

Drug Profile

YM 38336

Latest Information Update: 09 Aug 2002

Price : $50

At a glance

  • Originator Yamanouchi
  • Class Antiasthmatics; Irritable bowel syndrome therapies
  • Mechanism of Action Neurokinin 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Irritable bowel syndrome; Urinary incontinence

Most Recent Events

  • 30 Jul 1998 A preclinical study has been added to the Obstructive Airways Disease and Digestive System Disorders pharmacodynamics sections
  • 17 Jul 1998 No-Development-Reported for Urinary incontinence in Japan (Unknown route)
  • 20 Nov 1995 A study has been added to the Digestive System Disorders and Genitourinary Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top